SHORT REPORT:

Title: Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice

Authors: Xinyue Dong^{1,a}, Jun Ren^{1,b}, Zohreh Amoozgar^{1,c}, Somin Lee¹, Meenal Datta^{1,d}, Sylvie Roberge¹, Mark Duquette¹, Dai Fukumura¹ and Rakesh K. Jain¹.

Affiliations:

- Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114
- a. Current affiliation: Takeda Pharmaceutical Company Limited, Cambridge, MA 02139
- b. Current affiliation: Dynamic Cell Therapies, Inc., Boston, MA 02134
- c. Current affiliation: Sanofi, 270 Albany St., Cambridge, MA 02139
- d. Current affiliation: Department of Aerospace and Mechanical Engineering, University of Notre Dame, Notre Dame, IN 46556




Figure S1. Generation of murine EGFRvIII-CAR-T cells and EGFRvIII-expressing syngeneic

GBM cell lines. (**A**) Genetic maps of retroviral vectors encoding EGFRvIII targeting CAR. (**B**) Mouse T cells were transduced with retroviral constructs, and transduction efficiency was determined by assessing the Myc-tag on CAR-T cells 3 days post-transduction by flow cytometry. (**C**) Transduction efficiency of EGFRvIII in GBM tumor cells was determined by assessing the EGFRvIII expression on CAR-T cells 3 days post-transduction by flow cytometry. (**D**) CAR-T cells were incubated at a ratio of 1:1 with CT2A GBM cells, and IFN-γ release after 6 and 24-hr co-culture was measured by ELISA (n = 3). Error bars show \pm SEM. Statistical analysis was performed using one-way ANOVAs. ***p < 0.001.






Figure S1. EGFRvIII-GFP-CT2A-Gluc activity in blood (RLU/s) versus tumor volume in cubic millimeters as measured by in vivo micro ultrasound. In, natural logarithm. $R^2 = 0.78$




Figure S2. The effect of B20 treatment on the macrophages, neutrophils, or dendritic cells in GSC005 tumors as compared with PBS control. (A) Gating strategy of

CD45+/CD11b+/F4/80+/GR1- macrophages, Ly6C^{lo} monocytes and Ly6G+ neutrophils (gated on CD45+/CD11b+/F4/80-), and CD45+/TCR-/CD8a+ dendritic cells inside the GSC005 GBM tumors. (B) Percentage of macrophages, Ly6C^{lo} monocytes and Ly6G+ neutrophils and dendritic cells inside the GSC005 GBM tumors. Error bars show ± SEM. Statistical analysis was performed using Student's t-test.

Supplemental Movie SM1. Real-time multi-photon 3D video of live mouse brain treated with PBS (Video 1). GSC005 tumors were GFP labeled (green), and CAR-T cells were fluorescently labeled (red). Scale bar= $50 \mu m$.

Supplemental Movie SM2. Real-time multi-photon 3D video of live mouse brain treated with EGFRvIII-CAR-T cells (Video 2). GSC005 tumors were GFP labeled (green), and CAR-T cells were fluorescently labeled (red). Scale bar= $50 \mu m$.